LL-37
- Category
- Immune & Defense
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
A natural cathelicidin antimicrobial peptide, marketed for infection, biofilms, and wound healing. Its antimicrobial and wound-healing effects are moderately supported and rest largely on lab and animal work, with thin human data and speculative anticancer claims. The main safety gap is cell toxicity at high doses (including red blood cell rupture) plus a self-DNA autoimmune link. Not an approved US drug, and unregulated products sold online are of uncertain purity.
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.
Overview
LL-37 is the only antimicrobial peptide of its kind (cathelicidin) produced by the human body. This 37-amino-acid peptide is a critical component of your innate immune system, produced by skin cells, white blood cells, and the cells lining your airways and gut. It forms a shape (alpha-helix) that can punch holes in bacterial membranes, giving it direct germ-killing activity. Beyond fighting infections, LL-37 also promotes wound healing, stimulates new blood vessel growth, modulates inflammation, and helps coordinate the immune response.
How it works in the body
The only cathelicidin antimicrobial peptide in humans. It inserts into bacterial membranes, creating pores that kill pathogens directly. It also recruits immune cells to infection sites, promotes wound healing by stimulating cell migration, and modulates inflammation by binding and neutralizing bacterial endotoxin (LPS).
Research overview
LL-37 is the most extensively studied human antimicrobial peptide, with over 3,000 publications covering direct germ-killing activity, wound healing, immune modulation, and even anti-cancer applications. Small trials reported favorable healing predictors and granulation outcomes, but the larger 148-person venous-ulcer trial found no significant overall benefit. That trial's favorable large-ulcer subgroup findings require confirmation. A Phase I/II melanoma trial explored direct injection into tumors. While the preclinical data is extensive, clinical translation has been limited by practical challenges: the peptide is expensive to manufacture, breaks down quickly in the body, and can damage healthy cells at higher doses. Current research is focused on developing more stable synthetic versions, nanoparticle delivery systems, and combinations with conventional antibiotics to overcome these limitations.
Who researches LL-37?
Commonly researched by
People exploring tissue repair and injury recovery
Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.
People researching immune system support
Studied for immune modulation, antiviral, or antimicrobial properties.
People researching inflammation management
Studied for anti-inflammatory effects across various conditions.
People researching experimental oncology peptides
Studied for effects on cancer cell targeting or tumor biology in preclinical research.
Important considerations for
Those with Autoimmune conditions (psoriasis, lupus)
HighLL-37 is elevated in psoriatic lesions and may exacerbate autoimmune skin conditions. Forms DNA complexes that activate autoimmune pathways.
Those with Rosacea
ModerateLL-37 is pathogenically elevated in rosacea. Exogenous administration may worsen the condition.
Those who are pregnant or breastfeeding
AbsoluteNo reproductive safety data.
Safety & interactions
Do not use if
Autoimmune conditions (psoriasis, lupus)
HighLL-37 is elevated in psoriatic lesions and may exacerbate autoimmune skin conditions. Forms DNA complexes that activate autoimmune pathways.
Rosacea
ModerateLL-37 is pathogenically elevated in rosacea. Exogenous administration may worsen the condition.
General cautions
Pregnancy
AbsoluteNo reproductive safety data.
How to read the ratings
- Benefits
- = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
- Risks
- = level of concern: High · Moderate · Low · Theoretical
- Interactions
- = direction with this peptide: Protective / Synergistic · Caution · Neutral
Risk summary(6)
Rated by level of concern
At high concentrations LL-37 can damage human cells including red blood cells (hemolysis)
ModerateCiornei et al., AAC 2005 (PMID 15980359); review PMC12386566 (Int J Mol Sci 2025)
LL-37 is rapidly broken down by proteases, limiting half-life
ModerateReview PMC12386566 (Int J Mol Sci 2025); fragment-development literature (FBL 2021, 10.52586/5029)
LL-37 complexed with self-DNA can activate plasmacytoid dendritic cells (autoimmunity link)
ModerateLande et al., Nature 2007 (PMID 17994007); Lande et al., Nat Commun 2014 (lupus)
Bacteria can develop resistance to LL-37 through membrane modifications
ModerateNizet, Curr Issues Mol Biol 2006 (PMID 16450883)
LL-37 antimicrobial activity diminished by serum, salt, and divalent cations
HighCiornei et al., AAC 2005 (PMID 15980359)
The melanoma trial (NCT02225366) noted dermatologic toxicity at intratumoral injection sites
LowNCT02225366 (clinicaltrials.gov)
Interaction summary(5)
Rated by direction with this peptide
Vitamin D (cholecalciferol / calcitriol)
SynergisticLowVitamin D upregulates endogenous cathelicidin (CAMP/LL-37) transcription via a vitamin D response element, and supplementation raises circulating LL-37 in humans.
Gombart et al., FASEB J 2005 (PMID 15985530); Dixon et al., PMC3532295
Sodium phenylbutyrate (with or without vitamin D3)
SynergisticLowHuman dose-finding studies show phenylbutyrate induces macrophage LL-37 and acts synergistically with vitamin D3 to boost endogenous expression.
Mily et al., BMC Pulm Med 2013; Steinmann et al., PMID 25458314
Conventional antibiotics (colistin, aminoglycosides, beta-lactams)
SynergisticLowLL-37 shows additive-to-synergistic bacterial killing and biofilm disruption with several antibiotics against resistant Gram-negatives in vitro.
In vitro synergy literature (review PMC12386566, Int J Mol Sci 2025)
Heparin and anionic glycosaminoglycans
CautionTheoreticalPolyanions bind and sequester cationic LL-37, neutralizing its membrane-disrupting antimicrobial activity in vitro.
Ciornei et al., AAC 2005 (PMID 15980359); mechanism
Serum lipoproteins / HDL and albumin
CautionLowSerum proteins sequester LL-37, markedly reducing its antimicrobial potency while also lowering its cytotoxicity toward host cells.
Ciornei et al., AAC 2005 (PMID 15980359); SP-A/serum study PMC9464622
Known risks(6)
Dose-dependent cytotoxicity
At high concentrations, LL-37 can damage human cells including red blood cells (hemolysis) and other cell types. The venous leg ulcer trial showed the highest dose (3.2 mg/mL) was no better than placebo, suggesting a narrow therapeutic window.
Proteolytic degradation
LL-37 is rapidly broken down by proteases in blood and tissues, limiting its half-life and bioavailability in vivo. This necessitates local administration or modified analogs.
Potential autoimmune stimulation
LL-37 complexed with self-DNA can activate plasmacytoid dendritic cells and has been implicated in the pathogenesis of psoriasis and systemic lupus erythematosus. Individuals with autoimmune conditions should exercise caution.
Bacterial resistance development
While less common than antibiotic resistance, bacteria can develop resistance to LL-37 through membrane modifications, efflux pumps, and protease production.
Reduced activity in physiological conditions
LL-37 antimicrobial activity is diminished in the presence of serum, salt, and divalent cations found in physiological fluids, which may reduce in vivo efficacy compared to in vitro results.
Injection site reactions
The melanoma trial (NCT02225366) noted dermatologic toxicity at intratumoral injection sites, though this was expected given the high local concentrations used.
Drug interactions(4)
Immunosuppressants (e.g., cyclosporine, tacrolimus)
LL-37 modulates immune function and enhances immunosuppressive capabilities of mesenchymal stromal cells. Concurrent use with immunosuppressants may have unpredictable effects on immune regulation. Use with caution under medical supervision.
Conventional antibiotics
LL-37 may have synergistic antimicrobial effects when combined with certain antibiotics due to its membrane-disrupting mechanism facilitating antibiotic entry. This is an area of active research and could be beneficial but requires monitoring.
Corticosteroids (systemic)
Systemic corticosteroids suppress cathelicidin expression. Exogenous LL-37 administration during corticosteroid use may partially compensate for reduced endogenous production, but the net immunological effect is not well characterized.
NSAIDs
No direct interaction established. Both LL-37 and NSAIDs modulate inflammatory pathways; theoretical concern of altered wound healing dynamics when used concurrently.
Research & benefits
Evidence base
- Evidence Level
- Moderate
- Total Studies
- 3000
- Human Studies
- 5
A 34-person venous-ulcer trial reported improved healing predictors, and a 25-person diabetic-foot-ulcer trial found improved granulation. A larger 148-person venous-ulcer trial found no significant overall healing benefit; favorable subgroup findings were exploratory. Phase I melanoma trial (NCT02225366) completed. A small exploratory study evaluated oral LL-37 for COVID-19. Most evidence remains preclinical, and the clinical wound-healing evidence is mixed.
Researched for(6)
Rated by confidence in the evidence
Broad-spectrum antimicrobial activity
MediumDisrupts membranes of many bacteria, fungi, and enveloped viruses in laboratory tests.
Review PMC12386566 (Int J Mol Sci 2025); Ciornei et al., AAC 2005 (PMID 15980359)
Anti-biofilm activity
LowPrevents and breaks up bacterial biofilms in lab studies, not yet tested in people.
Overhage et al., Infect Immun 2008 (PMID 18411285)
Wound healing acceleration
MediumA human trial found topical use sped venous leg ulcer healing versus placebo.
Gronberg et al., Wound Repair Regen 2014 (PMID 25041740); Mahlapuu et al., Wound Repair Regen 2021 (PMC9298190)
Immunomodulation
MediumRecruits immune cells and adjusts inflammatory signaling up or down in cell and animal studies.
Lande et al., Nature 2007 (PMID 17994007); NCT02225366
Anticancer potential
SpeculativeAn early melanoma trial suggested immune activation, but effects on cancer stay unproven and may vary.
Coffelt et al., PNAS 2009 (doi:10.1073/pnas.0900244106; PMID 19234121, pro-tumor ovarian); NCT02225366
Anti-inflammatory effects
LowNeutralizes bacterial endotoxin and curbs excess inflammation in cell and mouse studies.
Nagaoka et al., PLoS One 2011 (LPS neutralization, PMC3196584); murine sepsis PMC7503894
Benefits(6)
Broad-spectrum antimicrobial activity
Anti-biofilm activity
Wound healing acceleration
Immunomodulation
Anticancer potential
Anti-inflammatory effects
Key studies(5)
Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial
Randomized controlled trial3411 weeks (3-week run-in, 4-week treatment, 4-week follow-up)Grönberg A, Mahlapuu M, Ståhle M, Whately-Smith C, Rollman O
Wound Repair and Regeneration
2014
Topical LL-37 at 0.5 mg/mL showed 6-fold higher healing rate vs placebo with 68% ulcer area reduction. Safe and well tolerated with no local or systemic adverse events.
Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial
Randomized controlled trial4 weeks (twice-weekly application)Miranda E et al.
Archives of Dermatological Research
2023
LL-37 cream demonstrated consistently greater granulation tissue formation vs placebo (p=0.006-0.037), but bacterial-colony reductions were not statistically significant. NCT04098562.
The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium
In vivo / in vitro translational studyHeilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, Ståhle-Bäckdahl M
Journal of Investigative Dermatology
2003
LL-37 peaks at 48h post-wounding and is absent in chronic ulcer epithelium. Blocking LL-37 inhibits re-epithelialization in a concentration-dependent manner, establishing its role in wound closure.
The Potential of Human Peptide LL-37 as an Antimicrobial and Anti-Biofilm Agent
Comprehensive reviewRidyard KE, Overhage J
Antibiotics (Basel)
2021
LL-37 demonstrates superior anti-biofilm activity compared to silver nanoparticles and conventional antibiotics. Broad-spectrum activity against ESKAPE pathogens. Limitations include proteolytic degradation, cytotoxicity at high concentrations, and high synthesis cost.
Wound healing activity of the human antimicrobial peptide LL37
Preclinical studyRamos R et al.
Peptides
2011
Topical application of synthetic and recombinant LL-37 increased vascularization and re-epithelialization in wound models, confirming dual antimicrobial and healing properties.
Regulation & availability
Why researchers look at it
Kills bacteria by physically punching holes in membranes — a mechanism far harder for microbes to evolve resistance against than conventional antibiotics — with mixed clinical wound-healing evidence: small positive studies and a larger venous-ulcer trial showing no significant overall benefit. Beyond infection control, it simultaneously promotes tissue repair, new blood vessel growth, and immune coordination, a multi-function profile no conventional antibiotic matches. If next-generation synthetic analogs overcome the current manufacturing and stability challenges, LL-37-based therapeutics could fill a critical gap in drug-resistant infections and non-healing wounds.
- Estimated cost
- No approved product and no verified reference price
- FDA status
- Not FDA-approved for any indication. LL-37 (also known as ropocamptide) has investigational drug status. It has been studied in Phase I/II clinical trials for wound healing and melanoma but has not advanced to Phase III registration trials. High production cost and stability challenges have slowed regulatory progression. No NDA or BLA has been filed as of early 2026.
- WADA status
- Not individually named in the 2026 List. S0 prohibits pharmacological substances without current governmental approval anywhere for human therapeutic use, unless covered elsewhere in the List. Athletes should confirm therapeutic LL-37's compound-specific status with their anti-doping organization.
- Prescribability
- LL-37 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA plans to ask its advisory committee about adding it before the end of February 2027. Human use remains investigational.
- Availability
- LL-37 is not FDA-approved. Some integrative and functional medicine clinics advertise injectable or topical LL-37, but these offerings do not establish lawful compounding eligibility. Its 503A bulks nomination was withdrawn, it is absent from current 503A Category 1 and the final bulks list, and clinical wound studies used investigational topical formulations. Availability varies by jurisdiction.
International status
EU
Not approved
US
LL-37 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use. FDA plans to ask its advisory committee about adding it before the end of February 2027.
Australia
Not approved
Regulatory timeline(8)
- 2003Heilborn et al. establish LL-37's role in wound re-epithelialization and its absence in chronic ulcers (Journal of Investigative Dermatology)
- 2011Ramos et al. confirm topical LL-37 increases vascularization and re-epithelialization in preclinical wound models
- 2014First RCT published: topical LL-37 safe and effective for venous leg ulcers with 6-fold healing rate improvement at 0.5 mg/mL (Wound Repair and Regeneration)
- 2014Phase I melanoma trial (NCT02225366) initiated at MD Anderson Cancer Center for intratumoral LL-37 injections
- 2018Dermatologic toxicity from intratumoral LL-37 in melanoma trial characterized and published
- 2021Comprehensive review establishes LL-37 as superior to silver nanoparticles for anti-biofilm activity (Antibiotics journal)
- 2023Second RCT: LL-37 cream enhances diabetic foot ulcer healing with significant granulation tissue formation (Archives of Dermatological Research, NCT04098562)
- 2026Ongoing research into stable LL-37 analogs, nanoparticle delivery systems, and synergistic antibiotic combinations to overcome bioavailability limitations
Sources & FAQs
Research sources(10)
- PubMed - LL-37 venous leg ulcer RCT
- PubMed - LL-37 diabetic foot ulcer RCT
- PubMed - LL-37 in wound re-epithelialization
- PMC - LL-37 antimicrobial and anti-biofilm review
- PubMed - LL-37 wound healing activity
- ClinicalTrials.gov - LL-37 melanoma Phase I
- PMC - LL-37 in cancer therapy review
- Nature - LL-37 oligomerization and channel formation
- PMC - LL-37 in autoimmune disease
- ScienceDirect - LL-37 pore-forming mechanism
Frequently asked questions(6)
What is LL-37 and where does it come from?
LL-37 is the only cathelicidin antimicrobial peptide found in humans. It is naturally produced by your immune cells (neutrophils, macrophages) and skin cells as a first-line defense against infections. The therapeutic form is a synthetic copy of this natural peptide.
How does LL-37 kill bacteria?
LL-37 has a strong positive charge that attracts it to negatively charged bacterial membranes. It inserts into the membrane and forms pores, causing the bacterial cell to leak and die. It can also enter bacteria and interfere with their DNA and protein machinery.
Is LL-37 effective against antibiotic-resistant bacteria?
Yes, LL-37 has shown activity against multidrug-resistant organisms including MRSA and multidrug-resistant P. aeruginosa. Its membrane-disrupting mechanism is different from conventional antibiotics, making cross-resistance less likely, though bacteria can develop resistance through membrane modifications.
Can LL-37 be taken orally?
Oral LL-37 has been explored in a small COVID-19 safety study, but the peptide is susceptible to proteolytic degradation in the GI tract. Most clinical and experimental use has involved topical application (for wounds) or subcutaneous/intramuscular injection.
How is LL-37 different from antibiotics?
Unlike conventional antibiotics that target a single bacterial process, LL-37 attacks bacteria through multiple mechanisms (membrane disruption, biofilm inhibition, intracellular targeting) while simultaneously boosting your own immune response and promoting tissue healing.
Is LL-37 safe?
In clinical trials, topical LL-37 at the concentrations studied was safe and well tolerated with no significant adverse events. However, at high concentrations it can be toxic to human cells (hemolytic and cytotoxic).